High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 42, Issue 6, 2017, Pages 1005-1011

  Golocorbin Kon, Svetlana ^a   Calasan, Jelena ^b   Milijasevic, Boris ^a   Vukmirovic, Sasa ^a   Lalic Popovic, Mladena ^a   Mikov, Momir ^a   Al Salami, Hani ^c  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOXAN; BILE ACID CONJUGATE; GLICLAZIDE; GLUCOSE; ANTIDIABETIC AGENT; BILE ACID; CHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MEGADOSE; DRUG UPTAKE; FEEDING; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LOADING DRUG DOSE; MICROENCAPSULATION; NONHUMAN; RAT; SINGLE DRUG DOSE; ANIMAL; BLOOD; DRUG INTERACTION; EXPERIMENTAL DIABETES MELLITUS; MALE; METABOLISM;

ANIMALS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLIC ACID; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG COMPOUNDING; DRUG INTERACTIONS; GLICLAZIDE; HYPOGLYCEMIC AGENTS; MALE; RATS;

EID: 85019666077     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-017-0415-0     Document Type: Article

References (39)

1. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract. 1991;14(Suppl 2):S21–36.
2. Holmes B, et al. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs. 1984;27(4):301–27.
3. Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism. 2003;52(8):29–34.
4. Riccio A, et al. Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. Metabolism. 1996;45(10):1196–202.
5. Cejvan K, et al. Gliclazide directly inhibits arginine-induced glucagon release. Diabetes. 2002;51(Suppl 3):S381–4.
6. Tsiani E, et al. Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology. 1995;136(6):2505–12.
7. Dollery C. ed. Therapeutic drugs. 2nd ed. London: Churchill Livingstone; 1999. pp. G52–56.
8. Palmer KJ, Brogden RN. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs. 1993;46(1):92–125.
9. Al-Kassas RS, Al-Gohary OMN, Al-Faadhel MM. Controlling of systemic absorption of gliclazide through incorporation into alginate beads. Int J Pharm. 2007;341(1–2):230–7.
10. Al-Salami H, et al. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet. 2008;33(2):101–6.
11. Mooranian A, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014;9:150–7.
12. Mooranian A, et al. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol. 2015;44(7):1642–53.
13. Mooranian A, et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 2015;16(1):45–52.
14. Mooranian, A., et al. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 2016;44(2):588–95.
15. Mathavan S, et al. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artif Cells Nanomed Biotechnol. 2016;44(6):1508–19.
16. Mooranian A, et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015;5(5):511–22.
17. Mooranian A, et al. Designing anti-diabetic beta-cells microcapsules using polystyrenic sulfonate, polyallylamine and a tertiary bile acid: morphology, bioenergetics and cytokine analysis. Biotechnol Prog. 2016;32(2):501–9.
18. Mikov M, et al. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. FEBS J. 2006;273:210.
19. Mikov M, et al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet. 2007;32(1):7–12.
20. Al-Salami H, et al. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol. 2008;30(2):107–13.
21. Mikov M, et al. The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008;33(3):137–42.
22. Al-Salami H, et al. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99–108.
23. Lalic-Popovic M, et al. Deoxycholic acid as a modifier of the permeation of gliclazide through the blood brain barrier of a rat. J Diabetes Res. 2013;2013:598603.
24. Mathavan S, et al. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycaemic effect in an animal model of Type-1 diabetes. Drug Deliv. 2016;23(8):2869–80.
25. Al-Salami H, et al. The influence of probiotics pre-treatment, on the ileal permeation of gliclazide, in healthy and diabetic rats. Arch Drug Inf. 2008;1(1):35–41.
26. Mooranian A, et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Devel Ther. 2014;8:1003–12.
27. Al-Salami H, et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacol Rep. 2008;60(4):532–41.
28. Al-Salami H, et al. Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Inf. 2008;1(1):35–41.
29. Al-Salami H, et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2009;34(1):43–50.
30. Stetinova V, et al. Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats. Biopharm Drug Dispos. 2007;28(5):241–8.
31. Mooranian A, et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20(6):702–9.
32. Lukivskaya O, Patsenker E, Buko VU. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci. 2007;80(26):2397–402.
33. Wu T, et al. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J Clin Endocrinol Metab. 2013;98(4):E718–22.
34. Kars M, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899–905.
35. Al-Salami H, et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Methods Find Exp Clin Pharmacol. 2008;30(2):107–13.
36. Davis TM, et al. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol. 2000;49(3):223–30.
37. Siow Y, Schurr A, Vitale GC. Diabetes-induced bile acid composition changes in rat bile determined by high performance liquid chromatography. Life Sci. 1991;49(18):1301–8.
38. Nervi FO, Severin CH, Valdivieso VD. Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochem Biophys Acta. 1978;529(2):212–23.
39. Thomson AB. Uptake of bile acids into rat intestine. Effect of diabetes mellitus. Diabetes. 1983;32(10):900–7.